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Abstract
Background: Most European and North American clinical practice guidelines recommend screening for asymptomatic
bacteriuria (ASB) as a routine pregnancy test. Antibiotic treatment of ASB in pregnant women is supposed to reduce
maternal upper urinary tract infections (upper UTIs) and preterm labour. However, most studies supporting the treatment
of ASB were conducted in the 1950s to 1980s. Because of subsequent changes in treatment options for ASB and UTI, the
applicability of findings from these studies has come into question. Our systematic review had three objectives: firstly, to
assess the patient-relevant benefits and harms of screening for ASB versus no screening; secondly, to compare the
benefits and harms of different screening strategies; and thirdly, in case no reliable evidence on the overarching
screening question was identified, to determine the benefits and harms of treatment of ASB.
Methods: We systematically searched several bibliographic databases, trial registries, and other sources (up to
02/2016) for randomised controlled trials (RCTs) and prospective non-randomised trials. Two authors independently
reviewed abstracts and full-text articles and assessed the risk of bias of the studies included. As meta-analyses were not
possible, we summarised the results qualitatively.
Results: We did not identify any eligible studies that investigated the benefits and harms of screening for ASB versus
no screening or that compared different screening strategies. We identified four RCTs comparing antibiotics with no
treatment or placebo in 454 pregnant women with ASB. The results of 2 studies published in the 1960s showed a
statistically significant reduction in rates of pyelonephritis (odds ratio [OR] = 0.21, 95 % confidence interval [CI] 0.07–0.59)
and lower UTI (OR = 0.10, 95 % CI 0.03–0.35) in women treated with antibiotics. By contrast, event rates reported by a
recent study were not statistically significantly different, neither regarding pyelonephritis (0 % vs. 2.2 %; OR = 0.37,
CI 0.01–9.25, p = 0.515) nor regarding lower UTI during pregnancy (10 % vs. 18 %; Peto odds ratio [POR] = 0.53,
CI 0.16–1.79, p = 0.357). Data were insufficient to determine the risk of harms. As three of the four studies were
conducted several decades ago and have serious methodological shortcomings, the applicability of their findings
to current health care settings is likely to be low. The recent high-quality RCT was stopped early due to a very
low number of primary outcome events, a composite of preterm delivery and pyelonephritis. Therefore, the results did
not show a benefit of treating ASB.
Conclusions: To date, no reliable evidence supports routine screening for ASB in pregnant women.
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Background
An amount of ≥ 105 bacteria per ml of freshly voided
urine and the absence of typical symptoms of urinary
tract infection (UTI) is referred to as asymptomatic bac-
teriuria (ASB) [1, 2]. The reported prevalence rates in
pregnancy range from 2 to 15 % [3–6]. Generally a be-
nign condition in most adults, in pregnant women ASB
has been associated with an increased risk of complica-
tions, especially upper UTIs (pyelonephritis) and pre-
term birth [7–9].
While pyelonephritis normally requires hospitalisation
and sometimes leads to severe complications such as
sepsis and respiratory problems [10], preterm birth is
the main contributor to infant morbidity and mortality.
Most clinical practice guidelines therefore recommend
screening for and antibiotic treatment of ASB in preg-
nancy [1, 2, 11, 12]. In most health care systems a screen-
ing programme for ASB in pregnancy has long been part
of routine maternal care [13].
These recommendations are based on data published
in the 1960s to 1980s and summarised in an update of a
Cochrane Review on the antibiotic treatment of ASB in
August 2015 [14]. Our systematic review had an
extended scope comprising three objectives: firstly, to
assess the patient-relevant benefits and harms of screen-
ing for ASB versus no screening; secondly, to compare
the benefits and harms of different screening strategies;
and thirdly, in case no reliable evidence on the overarch-
ing screening question was identified, to determine the
benefits and harms of treatment of ASB.
This systematic review is an update of a health tech-
nology assessment report of the benefits and harms of
screening for ASB in pregnancy conducted by the
German Institute for Quality and Efficiency in Health
Care (Institut für Qualität und Wirtschaftlichkeit im
Gesundheitswesen, IQWiG).
Methods
Protocol and methodological approach
The full (German-language) protocol and report [15], as
well as an English-language executive summary, are
available on the Institute’s website [16]. Both the prelim-
inary protocol and the preliminary report underwent
public commenting procedures. IQWiG’s responsibilities
and methodological approach are described in its
methods paper [15]. Only previously published studies
were used, so there was no requirement for ethical re-
view and consent.
Search strategy and study selection
Primary studies and secondary publications were searched
for in MEDLINE (1946 to January 2016) and EMBASE
(1974 to January 2016) via Ovid, and in the Cochrane
Central Register of Controlled Trials (January 2016). The
Cochrane Database of Systematic Reviews, the Database
of Abstracts of Reviews of Effects, and the Health Tech-
nology Assessment Database were screened to identify
systematic reviews. Reference lists of retrieved systematic
reviews were searched by hand. In addition, web-based
clinical trial registries were screened (ClinicalTrials.gov,
International Clinical Trials Registry Platform Search
Portal, and the EU Clinical Trials Register). The search
strategy included bibliographic index terms on bacteriuria
and pregnancy. The complete search strategy, which was
developed by one information specialist and checked by
another, is presented in Additional file 1. We also screened
publications cited in comments addressed to the Federal
Joint Committee, the decision-making body in the
German statutory healthcare system and IQWiG’s main
commissioning body. In addition, persons and parties who
had submitted written comments on the preliminary
report were asked to provide any additional relevant stud-
ies. Two reviewers independently screened titles and ab-
stracts of retrieved citations to identify potentially eligible
primary and secondary publications. The full texts of these
articles were obtained and independently evaluated by the
same two reviewers applying the full set of inclusion and
exclusion criteria. All documents retrieved from non-
bibliographic sources were also screened for eligibility or




We included randomised controlled trials (RCTs). If insuf-
ficient evidence was available from RCTs, we also planned
to include non-randomised interventional prospective
trials (referred to as controlled clinical trials: CCTs).
The eligibility criteria for the population, study and
control interventions, and outcomes are presented in
Table 1.
We searched for studies investigating at least one
predefined patient-relevant outcome. In this context,
the term ‘patient-relevant’ refers to how a person (in
this case, a mother or child) feels, functions, or survives
[17]. In addition, we planned to analyse data on the
following additional predefined non-patient-relevant
outcomes if they were reported in the studies included:
preterm birth > 32 − < 37 weeks of gestation, birth
weight 1500 − < 2500 g, and pre-eclampsia with un-
known symptom status.
Document characteristics
We included both published and unpublished studies if
a full-text document (e. g. journal article or clinical study
report) was available. We did not apply language or pub-
lication date restrictions. We excluded multiple publica-
tions not providing additional relevant information.
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Data extraction
The individual steps of the data extraction and risk of bias
assessment were conducted by one author and checked by
another; disagreements were resolved by consensus. We
extracted details of the studies using standardised tables
developed and routinely used by IQWiG.
We extracted information from each included study on:
(1) Study characteristics, including study design, length
of follow-up, sample size, location, and period in
which the study was conducted.
(2) Characteristics of the study participants, including
age, parity, present diabetes mellitus, history of UTI,
sociodemographic data, and dropout rate.
(3) Characteristics of interventions, including treatment
regimen and adjunct treatments.
(4) Inclusion and exclusion criteria, including method
of urine collection, diagnostic procedure(s), and
cut-offs used to identify study participants.
(5) Risk-of-bias items (see below).
Assessment of risk of bias
We assessed the risk of bias for individual studies, as well
as for each outcome, and rated these risks as “high” or
“low”. In individual studies the risk of bias was assessed by
determining the adequacy of the following quality criteria:
generation of random allocation sequence, allocation
concealment, blinding of participants and investigators,
and selective outcome reporting. As no CCTs were identi-
fied, no further details of the respective risk-of-bias assess-
ment planned are provided here. If the risk of bias on the
study level was rated as “high”, the risk of bias on the out-
come level was generally also regarded as “high”. The risk
of bias for each outcome was assessed by determining the
adequacy of the following quality criteria: blinding of
outcome assessors, application of the intention-to-treat
(ITT) principle, and selective outcome reporting.
Data analysis
We performed a synthesis and analysis of information
by means of the methods described below and presented
a summarising evaluation. Results of outcomes retrieved
from individual studies were described comparatively.
For the statistical analysis, we planned to primarily use
results from the ITT analysis as reported. If not pro-
vided, we calculated the required estimates of location
and dispersion. We reported the treatment effects as
ORs (including 95 % CIs) for binary data and planned to
report mean differences (including 95 % CIs) for con-
tinuous data. We planned to assess potential heterogen-
eity of effect sizes by means of the I2 statistic and a
statistical heterogeneity test [18]; if relevant heterogen-
eity was shown (p < 0.2), we planned to calculate pooled
estimates only in justified exceptional cases. As meta-
analyses were not feasible, we assessed the results of the
individual studies. We performed sensitivity analyses to
explore the potential impact of missing data.
Results
As we did not identify any eligible studies investigating
the benefits and harms of screening for ASB versus no
screening, or the advantages and disadvantages of differ-
ent screening strategies, our results focus on the treat-
ment of ASB.
Literature search
We identified four eligible studies out of 4288 references
retrieved from bibliographic databases (Fig. 1): Elder et
al. 1966 [19], Mulla 1960 [20], Kazemier et al. 2015 [21],
and Williams et al. 1969 [22]. All four studies were
RCTs assessing the treatment of ASB, one of which
Table 1 Eligibility criteria
Questions 1 and 2 (ASB screening) Question 3 (ASB treatment)
Population • Pregnant women taking part in routine maternal care
• Without symptoms of UTI
• With unknown ASB status
• Pregnant women with ASB detected in
screening
Study intervention • Any ASB screening strategy followed by treatment, if necessary • Any treatment for ASB
Control intervention • No ASB screening, but treatment if symptoms of UTI occur (question 1)
• Any other ASB screening strategy followed by treatment, if necessary
(question 2)
• No treatment or placebo
Patient-relevant outcomes • Pyelonephritis
• UTI
• Symptoms linked directly or indirectly to UTI (e. g. headache or visual impairment as symptoms of pre-eclampsia, fever)
• Infant morbidity (e. g. respiratory distress syndrome, sepsis, cerebral haemorrhage, necrotising enterocolitis)
• Perinatal mortality
• Early preterm birth (< 32 weeks of gestation)
• Very low birth weight (< 1500 g)
• Health-related quality of life and psychosocial functioning
• Any adverse event
ASB asymptomatic bacteriuria, UTI urinary tract infection
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was embedded in a multicentre cohort screening
study (Kazemier 2015).
Study characteristics
Table 2 presents the main characteristics of the four
studies included. Three were published in the 1960s.
One study enrolled patients from 2011 to 2013 and the
results were published in 2015. The four studies investi-
gated the effect of antibiotic treatment in 454 pregnant
women with ASB. The total number of randomised par-
ticipants is unknown, due to a lack of data in one study
(Williams et al.). Only one study (Kazemier et al.) pro-
vided information on patient characteristics.
Elder et al. investigated the effect of sulfasymazine on
multiple laboratory parameters and selected adverse
events in pregnant women with and without ASB. Py-
elonephritis cases were also mentioned but event rates
were missing.
Kazemier et al., a multicentre prospective cohort study
with an embedded RCT conducted in the Netherlands,
included a cohort of low-risk pregnant women screened
for ASB using the dip slide method. Consenting ASB-
positive women were randomised to nitrofurantoin or
placebo. The aim of the RCT was to evaluate the effect
of nitrofurantoin on a composite primary outcome,
preterm delivery and pyelonephritis, as well as on a
number of secondary maternal and neonatal outcomes.
The study was stopped early after the planned interim
analysis when data were available for 30 % of the
planned sample, as pyelonephritis events were much
less frequent than expected in both the treatment and
control groups.
Mulla provided only a vague description of the study
characteristics (see Table 2). In particular, details were
missing on the diagnostic strategy used. No information
was provided on the specific catheter, the number of
positive test results, the cut-offs, and the diagnostic algo-
rithm (i.e., whether both tests were used as a combin-
ation and, if so, how the test results were combined to
diagnose ASB).
Fig. 1 Flowchart of study selection
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Table 2 Study characteristics
Comparison study Study design Participants randomised
(intervention / control)









Inclusion and exclusion criteria
Sulphasymazine vs. placebo
Elder [19] RCT, double-blind,
parallel
106 (54 / 52) Sulphasymazine 0.5 g/d until
birth or onset of pyelonephritis;
if bacteriuria persisted medication
was changed to nitrofurantoin or









Clean voided / UC I: pregnant; same species of bacteria in first 3
uncontaminatedb specimens, ≥ 104 /ml in one
and ≥ 105/ml in 2
E: > 32th week of gestation at first examination
Sulphadimethoxine vs. no treatment
Mulla [20] RCT, blinding
not stated
100 (50 / 50) Sulphadimethoxine 2 x 250 mg/d








Catheter (not specified) /
UC and “stained smear”c
not further specified
I: 30th – 32th week of gestation; bacteriuria
(not specified)
E: not stated
Sulphadimidine vs. no treatment
Williams [22] RCT, blinding
not stated
Not stated (85 / 78)d Sulphadimidine 3 x 1 g 7 days;
if bacteriuria persisted until
2 to 3 weeks after finishing
primary treatment, then
nitrofurantoin 2 x 100 mg/d for
7 days if still persisting ampicillin





Voided midstream / UC I: < 30th week of gestation at recruitment;






RCT, embedded in a
multicentre cohort study
85 (40 / 45) Nitrofurantoin 100 mg 2x/d
5 days, self-administered if
follow-up culture positive one
week after end of treatment,
1x repeated (masked) medication
at the same dose and schedule
NL / hospitals
and ultrasound
centres / 10 /
2011 – 6 / 2013e
Until 08 /
2014
Not stated / dip slide
with two culture media
I: women≥ 18 years with a singleton pregnancy
between 16 and 22 weeks; without symptoms of
UTI; ≥ 1x105 CFU /ml of a single microorganism
or when 2 different colony types were present
but 1 with≥ 1x105 CFU / ml
E: history of preterm delivery < 34 weeks; warning
signs of an imminent preterm delivery; fetal
congenital malformations; antibiotic use within
2 weeks of screening; known glucose-6-phosphate
dehydrogenase deficiency; hypersensitivity to
nitrofurantoin; risk factors for complicated UTI
CFU colony forming units, GB Great Britain, I inclusion criteria, E exclusion criteria, g gram, ml millilitre, NL Netherlands, RCT randomised controlled trial, UC urinary culture, USA United States of America, UTI urinary
tract infection
aExact length of follow-up not stated, but outcomes were assessed that occurred immediately after birth
bContamination was defined as a specimen with “large numbers of organisms that were likely to be of vaginal origin”
cThe diagnostic strategy to identify the study population consisted of two different diagnostic tests. No details were reported on the specific catheter, the number of positive test results required, the cut-offs used,
or the diagnostic algorithm (i.e., whether both tests were used as a combination and, if so, how the test results were combined to diagnose ASB)
dOf originally 211 pregnant women with gram-negative asymptomatic bacteriuria, a subgroup of participants restricted to those with coliform bacteria was analysed in the relevant trial














Williams et al. reported the results of two consecutive
trials, one of which is relevant for this systematic review.
Prior to the relevant trial, the majority of participants
had taken part in a preceding trial where they had been
hospitalised for 24 h, while fluid intake had been re-
stricted to a minimum.
Risk of bias
In the three studies from the 1960s the risk of bias was
high for nearly all items considered, while the recent
trial (Kazemier et al.) had a low risk of bias on the study
and outcome level (see Table 3).
Effects of interventions
Pyelonephritis and lower UTI
Williams et al. reported results on pyelonephritis, Mulla
on lower UTI, and Kazemier et al. on both outcomes
(Table 4): In Williams et al. and Mulla, respectively, anti-
biotic treatment statistically significantly reduced the in-
cidence of pyelonephritis (6 % vs. 23 %; OR = 0.21, 95 %
CI 0.07–0.59, p = 0.002) and of lower UTI (6 % vs. 40 %;
OR = 0.10, 95 % CI 0.03–0.35, p < 0.001). By contrast,
event rates reported by Kazemier et al. were not statisti-
cally significantly different for pyelonephritis (0 % vs.
2.2 %; OR = 0.37, CI 0.01–9.25, p = 0.515) and lower UTI
treated with antibiotics during pregnancy (10 % vs. 18 %;
POR = 0.53, CI 0.16–1.79, p = 0.357) or during a 6-week
postpartum period (see Table 4). Because of substantially
different study periods (1960s vs. 2010s), pooling of data
was not feasible.
In the analysis of pyelonephritis rates in Williams et al.
the proportion of excluded participants was high
(22.7 %). We therefore performed a sensitivity analysis
to assess the impact of missing data, assuming that all
participants (211 instead of the 163 actually analysed)
were included, and both the treatment and control
group were of equal size (Table 5). Under the ass-
umption that no events had occurred in excluded
participants, the effect remained statistically significant.
Assuming that additional events had occurred only in
excluded women of the treatment group, the effect
remained statistically significant until at least four add-
itional events occurred in this group (with the events in
the control group remaining unchanged).
Preterm birth
One study (Kazemier et al.) provided data on preterm
birth. Preterm birth rates (<37 weeks of gestation)
were low in both groups and there was no statistically
significant difference (5.0 % vs. 4.4 %, Peto odds ratio
[POR] = 1.13, CI 0.15–8.35, p = 0.975). Only one pre-
term birth event considered patient-relevant, i.e. pre-
term birth < 32 weeks, occurred in the interventional
arm (see Table 4).
Infant morbidity
Only one study (Kazemier et al.) contained analyses of
infant outcomes. Event rates, in general, were low and
did not reveal any statistically significant difference be-
tween study groups (see Table 4).
Perinatal mortality
One study reported data on perinatal mortality (Kazemier
et al.). The difference was not statistically significant, as
there was only one case in the interventional arm (see
Table 4).
Adverse events
The available data did not allow conclusions to be drawn
on adverse events, as in one study (Elder et al.) the event
rate in the control group was not clearly stated, while no
events (Mulla) or very few (Kazemier et al.) occurred in
the other two studies (see Table 4). We therefore could
not determine the risk of adverse events under antibiotic
treatment, placebo or no treatment.


















Elder [19] unclear unclear yes / unclear / unclear uncleara, b noc nod high
Mulla [20] unclear unclear no / no / unclear noa, e noc, f unclear high
Williams [22] unclear unclear no / no / unclear noa, g noc noh high
Kazemier [21] yes yes yes / yes / yes yes yes yes low
aSample size planning, predefinition of study outcomes and their analysis not reported
bThe outcome “kernicterus” was reported together with other adverse outcomes, some of which were reported for only one study group
cPatient flow unclear; unclear whether information on inclusion and exclusion criteria was complete
dSome participants were excluded from the analysis; information on study discontinuations was insufficient
eThe outcome “preterm labour” was reported only for the control group; one outcome usually reported in association with preterm labour, preterm birth, was not
reported here
fThe outcome “cystopyelitis” was not defined and it was therefore unclear whether upper and / or lower UTI were included
gResults of one outcome not relevant to this assessment were reported incompletely
hSome participants were excluded from the analysis; the reasons were not stated
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Other outcomes
None of the studies reported data on further predefined
patient-relevant outcomes such as symptoms linked
directly or indirectly to UTI, birth weight < 1500 g,
health-related quality of life, and psychosocial functioning.
One study reported data on the predefined non-patient-
relevant outcome “pre-eclampsia” (Kazemier et al.)
without revealing any statistically significant difference
between study groups (5 % vs. 2.2 %, POR = 2.24,
CI 0.23–22.22, p = 0.596).
Table 4 Results
Outcome measure Study Treatment group Control group Difference between groups
Specification N Events (%) N Events (%) OR [95 % CI]; p-value
Pyelonephritis
Kazemier [21] 40 0 (0) 45 1 (2.2) 0.37a [0.01; 9.25]a; 0.515b
Williams [22] 85c 5 (6) 78c 18 (23) 0.21a [0.07–0.59]a; 0.002b
Lower UTI
Treated with AB during pregnancy Kazemier [21] 40 4 (10) 45 8 (18) POR 0.53a [0.16; 1.79]a; 0.357b
Recurrent UTI treated with AB during pregnancy Kazemier [21] 40 0 (0) 45 1 (2.2) 0.37a [0.01; 9.25]a; 0.515b
Treated with AB postpartum (within 6 weeks) Kazemier [21] 40 3 (7.5) 45 1 (2.2) POR 3.20a [0.43; 23.63]a; 0.296b
Pre- and post-partald Mulla [20] 50 3 (6) 50 20 (40) 0.10a [0.03–0.35]a; < 0.001b
Preterm birth
< 37 weekse Kazemier [21] 40 2f (5) 45 2 (4.4) POR 1.13a [0.15; 8.35]a; 0.975b
< 32 weeks Kazemier [21] 40 1 (2.5) 45 0 (0) 3.46a [0.14; 87.26]a; 0.357b
Infant morbidity
Kernicterus Elder [19] 54 0g 52 0g n. a.
Composite severe morbidityh Kazemier [21] 40 0 (0) 45 2 (4.4) 0.21a [0.01; 4.61]a; 0.220b
Admission to NICU Kazemier [21] 40 2 (5) 45 0 (0) 5.91a [0.28; 126.85]a; 0.169b
Neonatal sepsis confirmed with culture Kazemier [21] 40 0 (0) 45 2 (4.4) 0.21a [0.01; 4.61]a; 0.220b
Congenital abnormalities Kazemier [21] 40 0 (0) 45 1 (2.2) 0.37a [0.01; 9.25]a; 0.515b
Infant mortality
Perinatal death Kazemier [21] 40 1 (2.5) 45 0 (0) 3.46a [0.14; 87.26]a; 0.357b
Adverse events
Vomiting Elder [19] 54 1 52 0 n. a.
Rashes, pruritus Elder [19] 54 0f 52 0f n. a.
Photosensitivity Elder [19] 54 0f 52 0f n. a.
Discontinuations due to adverse events Mulla [20] 50 0 50 0 n. a.
Pre-eclampsiae Kazemier [21] 40 2 (5) 45 1 (2.2) POR 2.24a [0.23; 22.22]a; 0.596b
HELLP syndrome Kazemier [21] 40 2 (5) 45 0 (0) 5.91a [0.28; 126.85]a; 0.169b
Kidney stones, cholestasis Kazemier [21] 40 0 (0) 45 0 (0) RD 0 [-9,4; 10,5]
Thrombo-embolic events Kazemier [21] 40 0 (0) 45 0 (0) RD 0 [-9,4; 10,5]
Endometritis (within 6 weeks of delivery) Kazemier [21] 40 0 (0) 45 0 (0) RD 0 [-9,4; 10,5]
Mastitis (within 6 weeks of delivery) Kazemier [21] 40 1 (2.5) 45 1 (2.2) POR 1.13a [0.07; 18.41]a; 0.997b
AB antibiotics, CI confidence interval, CSZ convexity, symmetry, z score, HELLP haemolysis, elevated liver enzymes, low platelet count syndrome, n. a not available,
NICU Neonatal Intensive Care Unit, OR odds ratio, POR Peto odds ratio, RD risk difference, UTI urinary tract infection
aIQWiG’s own calculation
bIQWiG’s own calculation, unconditioned exact test (CSZ method as described in [25])
cNumber of participants analysed; number of randomised participants not stated
dThe outcome was named either cystopyelitis or symptomatic UTI; neither term was defined. It was therefore unclear which stage of UTI the reported outcome
represented. Following a conservative approach, we classified the outcome as lower UTI. However, it is possible that cases of upper UTI were also included
eConsidered a non-patient-relevant outcome
fOne event is also included in preterm births < 32 weeks
gIt is unclear whether the reported event rate relates to both study groups; alternatively, the event rate may relate solely to the treatment group or to any
pregnant participant with or without bacteriuria
hRespiratory distress syndrome, necrotizing enterocolitis, intraventricular haemorrhage, bronchopulmonary disease, sepsis
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Discussion
Summary of evidence
No studies were identified on the primary research ques-
tion, the benefit of screening for ASB versus no screening.
Four RCTs, of which three had a high risk of bias,
included data on 454 patients and provided limited in-
formation on the benefits and harms of antibiotic treat-
ment for women with ASB. Data collected more than
50 years ago indicate a reduction in the risk of UTIs and
pyelonephritis for women receiving antibiotic treatment,
whereas recent results of a high-quality RCT failed to
show any statistically significant difference.
The inconsistent results and the fact that three studies
were conducted more than 50 years earlier than the
most recent study raise the question of the applicability
of their findings.
Applicability
As the screening tests used in Mulla were not described,
it is not known how women who benefited from treat-
ment were identified. In Williams et al., the above-
mentioned interventions preceding the relevant trial
caused urinary concentration, an increase in the risk of
nosocomial infections, and a delay in treatment. The
setting created differs considerably from current routine
maternity care and may interact with the UTI outcomes
described below [23, 24]. This means that, although both
trials suggest a preventive effect of treatment of ASB
with regard to upper and lower UTI, the results do not
allow conclusions to be drawn about today’s pregnant
women in current health care settings. This is also
reflected in the results of the study by Kazemier et al.
Consequently, the benefit of treatment of ASB to pre-
vent upper and lower UTI is regarded as not proven.
Besides, further aspects challenge the applicability of
the three studies from the 1960s. None of them con-
tained details on age, parity, previous and concomitant
diseases, and sociodemographic data of the study popu-
lation. It was thus difficult to judge comparability with
today’s pregnant women. Factors that have undergone
considerable changes since the 1960s and may influence
the effects of treatment of ASB include the content and
scope of routine maternal care services, the general health
status and demographic characteristics of pregnant
women, as well as the further development of diagnostic
procedures. In summary, these factors have resulted in a
lower baseline risk of pyelonephritis [21].
The study medication in the three studies from the
1960s consisted primarily of sulphonamides, while only
the recent Dutch study used nitrofurantoin, a drug cur-
rently used as a first-line treatment option for ASB.
Comparison with previous research
Due to differing inclusion and exclusion criteria, the
above-mentioned Cochrane Review [14] included far
more studies than our review (14 randomised and quasi-
randomised trials). The Cochrane Review considered the
primary outcomes pyelonephritis, low birth weight, and
preterm birth. A meta-analysis of 11 of the 14 studies
showed a statistically significant decline in pyeloneph-
ritis rates under antibiotic treatment compared with no
treatment (RR [relative risk] = 0.23, 95 % CI 0.13–0.41,
p < 0.001).
The authors of the Cochrane Review conclude that
antibiotics are effective in preventing pyelonephritis, but
also state that the methodological shortcomings of the
trials included affect the strength of their conclusions.
However, our review comprises results of the first trial
in this field that has been conducted since the 1980s,
which leads to considerable changes in the judgement of
the benefits of screening and treating ASB.
Strengths and limitations (study and review level)
As we anticipated publications of varying quality and
age, the inclusion and exclusion criteria for the study
population were applied rather strictly in order to obtain
sufficiently conclusive data. We placed particular em-
phasis on the requirement that the population should
consist solely of asymptomatic women. When we could
not rule out that symptomatic women were included,
the study was not considered. This resulted in a study
pool of only four eligible studies.
The existing evidence derived from RCTs refers only to
the treatment of ASB. RCTs investigating the overarching
Table 5 Sensitivity analysis
Outcome measure Treatment group Control group Difference between groups
Study N Events (%) N Events (%) OR [95 % CI]; p-value
Pyelonephritis
Williams [22] Sensitivity analysis I 106a 5 (5) 105a 18 (17) 0.24b [0.19–1.05]b; 0.004c
Williams [22] Sensitivity analysis II 106a 9 (8)d 105a 18 (17) 0.45b [0.19–1.05]b; 0.066c
CI confidence interval, CSZ convexity, symmetry, z score, OR odds ratio
aIQWiG’s own calculation: all participants included (211 instead of the 163 actually analysed); both the treatment and control group were of equal size
bIQWiG’s own calculation
cIQWiG’s own calculation, unconditioned exact test (CSZ method as described in [25])
dThe level of significance would not be missed until at least four additional events occurred in the treatment group while no additional events occurred in the
control group (assumption)
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question, that is, whether a screening programme for de-
tection of ASB is beneficial, have still not been conducted.
However, the results of the Dutch ASB cohort study show
that, with access to high-quality health care and generally
good maternal health status, a routine ASB screen-and-




To date, no RCTs are available that assess the benefits
and harms of screening for ASB. The available evidence
is limited to four treatment trials: three with serious
methodological shortcomings and questionable applic-
ability to current medical practice and one low-risk-of-
bias trial that was stopped due to a very low number of
pyelonephritis events in both the treatment and control
group. Consequently, no conclusions can be drawn on
whether the benefits of screening for ASB outweigh the
potential harms. However, no reliable evidence supports
routine screening for ASB in pregnant women.
Implications for future research
Due to the low number of women randomised (n = 85),
the randomised part of the study by Kazemier et al. pro-
vides little additional information on the question as to
whether treatment of ASB is beneficial. However, the
low absolute risk of pyelonephritis in low-risk pregnan-
cies questions current practice. Taking this low risk into
account, future trials have to be planned on a larger
scale to achieve sufficient statistical power to either con-
firm or adjust current recommendations on screening
for and treatment of ASB. However, as long as there are
no new studies indicating the need to screen and treat
ASB in pregnancy, screening is not supported by clinical
evidence.
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